Home » Pharmaceuticals

Chagas Treatment Drug Price to Be Raised by Martin Shkreli

Turing Pharmaceutical’s founder Martin Shkreli was the cause of a big stir after he jacked the price of an old drug that AIDS patient take from its original $13.50 per pill to $750 earlier in the year, after he suggested that the new company  would raise prices of the drug for the possible fatal infection disease Chagas. The Trypanosoma cruzi parasite is what causes Chagas. The parasite is found in feces of what is called the kissing bug. The condition could lead to difficulty in swallowing and defecating and might lead to heart problems year... 
 

Pfizer to Tie the Knot with Allergan in Deal Worth $160 Billion

Pfizer and fellow drug maker Allergan announced Monday morning that they would be merging in a huge deal of $160 billion that would create the largest drug maker in the world, producing treatments that vary from Botox to Lipitor. The deal has been structured as “reversed-merger” as the smaller Allergan, based in Dublin, is buying Pfizer based in the U.S. It likely will renew the concern in Washington, D.C. over the corporate inversions where companies with a U.S. domicile are buying or bought by a foreign company to reduce its corporate tax... 
 

Valeant Drops Mail-Order Pharmacy Philidor

Valeant Pharmaceuticals International a maker of drugs, whose practices of aggressive pricing have helped it become a lightning rod for much criticism, announced on Friday it was ending a relationship it had with a pharmacy it used to bolster sales of its most expensive drugs. Valeant, which is based in Quebec, said it was severing all its ties with Philidor Rx Services and Philidor informed Valeant it would shut its operations as quickly as possible. The move comes after the largest three drug benefit managers in the U.S. – Express Scripts, OptumRx... 
 

Antipsychotic Long Lasting Drug Approved by FDA

The U.S. Food and Drug Administration has approved a new drug for schizophrenia by Alkermes PLC a biotech company in Ireland with executives based in Waltham. The new drug, Aristada, is a longer acting version of Abilify an antipsychotic best selling drug that earned over $9 billion last year worldwide, prior to losing its protection from its patent this past April. Aristada, which is administered through injection, dissolves slowly during a period of four to six weeks and negates the need for a daily pill to be taken. Aristada, said one doctor... 
 

Teva Acquires Rimsa the Pharmaceutical Company in Mexico

Teva Pharmaceuticals Industries will acquire Representacions e Investigaciones Medicas a pharmaceutical manufacturing as well as distribution company based in Mexico and known commercially as Rimsa. This deal includes a large portfolio of companies and products, assets, intellectual property and patents for pharmaceuticals in Europe and Latin America, in a cash-free, debt free set of transaction for $2.3 billion in total. Through this acquisition, Israel-based Teva will become the largest pharmaceutical business in Mexico. Teva is expecting the... 
 

WHO Calls For Early HIV Drug Treatment for All

Everyone who has HIV should receive antiretroviral drugs as early as possible following their diagnosis, which means over 37 billion people globally, should be receiving the treatment said the (WHO) World Health Organization on Wednesday. Recently complete clinical trials confirmed early use of the antiretroviral drugs help to extend the lives of people with the virus that cause AIDS and can lower the risk of the disease being transmitting between partners, said the WHO in a prepared statement that set out the new goals for its 194 members. Under... 
 

Collegium Painkiller Given Green Light from FDA Panel

The experimental opioid painkiller by Collegium Pharmaceutical has moved another step closer to FDA approval after a panel of expert advisers to the United States Food and Drug Administration voted unanimously in favor of its painkiller. The panel’s vote was contrary to a recommendation by staff at FDA, which on Wednesday had expressed a concern that the painkiller, which is administered orally could be used incorrectly leading to overdoses. The expert panel voted 23 to 0 in support of approving the drug. However, the FDA is not obliged to follow... 
 

Vital Therapies Stock Plunges Following Failed Trial For Liver Therapy

Vital Therapies Inc lost nearly 75% of its market value on Friday after the company announced that its therapy for the liver failed to reach its main goal in a recent late-stage study, which raised doubts about the treatment’s future. The company released a statement saying it would stop two studies that were ongoing of the therapy which is cell-based, that is aimed at treating liver diseases that are alcohol induced such as alcoholic hepatitis, fatty liver disease and cirrhosis. The liver assist system known as ELAD or extracorporeal liver assist... 
 

Endo International Revenue and Earnings Beat Targets

Endo International on Monday posted adjusted earnings that were better than had been expected during its second quarter, as the sales were given a boost from its recent acquisitions, although its discontinued operation hit its bottom line. Endo, which last year relocated from Pennsylvania to Ireland, is one of many pharmaceutical companies using foreign addresses that are lower in taxes, as a springboard for making acquisitions within the U.S., which has a corporate tax that is one of the highest anywhere in the world. Over the last two years, Endo... 
 

Allergen Bid Might Be Better for Teva

Following months of battling in its hostile takeover bid for Mylan, its rival, Teva Pharmaceutical’s move to acquire Allergan’s generic drug segment might instead be a smoother course that could bring in bigger and faster returns. Teva, which is based in Israel, is the largest generic drug maker in the world and in advanced negotiations with Allergan to purchase its generic drugs business for $40 million to $45 million, according to someone familiar with the situation. News of this deal first broke Saturday when the $40 billion Teva bid for... 
 

Biogen Slashes Forecast on Weakness of Tecfidera

Biogen Inc announced on Friday that it has slashed its outlook for revenue and earnings for the full year as its growth in sales for its multiple sclerosis drug is still weakening. Biogen said it expects to have earnings per share of $14.25 to $14.70, which is down from its guidance released earlier of between $15.45 and $15.85 per share in earnings. Biogen has forecasted growth in revenue of between 6% and 8%, which is down from its growth forecast earlier of between 14% and 16% that was released in January. The company cited new expectations for... 
 

Celgene Investing $1 Billion in Juno Therapeutics

Juno Therapeutics shares soared on Tuesday a day after Celgene a bigger drug developer announced its plans to invest close to $1 billion in the company mostly through purchases of stock as part of a new collaboration to develop autoimmune disease and cancer treatments. Celgene agreed to pay $150 million now and purchase 9.1 million of Juno shares at a price of $93 apiece. The portion of stock totals close to $850 million and the price was close to double the price of Juno stock last Friday that closed at $46.61. The collaboration amongst the two... 
 

Bayer Sells Diabetes Care to Panasonic Healthcare

Bayer entered into an agreement with Panasonic Healthcare Holdings to sell its Diabetes Care company. Panasonic Holdings is backed by the Panasonic Corp and KKR and the sales price it has agreed to pay is $1.15 billion, said company officials. The deal is expected to be completed during the first three months of 2016. This is the second attempt by Bayer to divest its business of blood glucose monitoring which has different brands including Microlet, Elite, Breeze and Contour. Bayer attempted to sell the business during 2012 and started those efforts... 
 

Valeant Nearing Deal to Acquire Salix for $10 Billion

Valeant Pharmaceuticals, the drug maker based in Canada is closing in a deal to purchase Salix Pharmaceuticals the gastrointestinal drug maker for an estimated $10 billion. A deal, said those close to the situation, could be announced early Sunday. Valeant is reportedly paying a cash price of $158 a share, just above the closing stock price for Salix on Friday of $157.85. The purchase by Valeant of Salix marks a return to deal making for the Canadian pharmaceutical company, which failed last year in its bid to acquire Allergan the maker of Botox.... 
 

AstraZeneca Acquiring Respiratory Drug Segment from Actavis

AstraZeneca announced it was paying $600 million for the rights to the brand respiratory drugs segment of Actavis in North America, as the drug maker reported a drop in profits for the fourth quarter that was steeper that was expected. The drug maker based in the UK posted its first revenue growth for a full year since 2011, but its earnings fell because of increasing its investment in its research and development arm as well as in marketing. Sales are forecasted to decline again in 2015 as competition from generic drug makers arrives for Nexium... 
 

Merck & Co Acquiring Cubist Pharmaceuticals

Merck & Co is set to acquire antibiotics maker Cubist Pharmaceuticals in a deal that is estimated to be between $7 billion and $8 billion. A report cited a source that said Merck would pay Cubist close to $102 a share with an official announcement to come during the early part of this week. Cubist Pharmaceuticals is the maker of Cubicin, which was approved initially in 2003 by the Food and Drug Administration for treating skin infections and received approval three years later as a drug to treat infections in the bloodstream. The company has... 
 

Actavis Close to Deal to Acquire Allergan for $64 Billion

Actavis Plc is near a deal to acquire Allergan Inc for an estimated $64 billion, a deal that would help the Botox maker rebuff the hostile advance of Valeant Pharmaceuticals International, said people that have knowledge of the deal. A deal might be announced on Monday, said those same people. Actavis will play over $210 per share in stock and cash for Allergan. The bid includes a larger percentage of cash than the current offer from Valeant. The breakup fee is close to $2 billion. The two companies had tried to narrow a difference of $3 billion... 
 

Eli Lilly Earnings Meet Expectations

Eli Lilly & Company reported adjusted earnings for the third quarter of 66 cents per share that were in line with estimates on Wall Street but were 41% lower than earnings from the same period one year ago. Revenue for the third quarter was down 16% to just over $4.87 billion, which reflected the competition from generic drugs for Evista and Cymbalta in the United States. However, revenue was slightly higher than Wall Street estimates of 4.83 billion. Earnings, which include special items, declined by 58% to just 47 cents a harsh during the... 
 

Horizon Pharma Moves Overseas Defying Lawmakers

Despite an increasing amount of criticism from Washington lawmakers, a drug maker officially left the U.S. and opened its corporate offices in Ireland in a move that was designed to lower its taxes. Horizon Pharma closed its acquisition of $587 million for Vidara Therapeutics International a pharmaceutical company based in Ireland. The deal allows Horizon to move its corporate headquarters officially over to Dublin The announcement on Friday was on the same day that two U.S. Senators, Illinois’ Dick Durbin and Ohio’s Sherrod Brown, both who... 
 

Roche Acquires InterMune

Roche the pharmaceutical giant based in Switzerland is expanding its treatments for respiratory disease through its acquisition of InterMune a drug maker in Brisbane for more than $8.3 billion, said both companies. Roche agreed to acquire the drug maker at $74 a share in a transaction of all cash, price that was a premium of 38% over the closing price of the company stock on Friday of $53.81. This acquisition takes place as InterMune expects to win an approval that has been long coveted in the U.S. for pirfenidnoe, its treatment for the rare and... 
 

Sanofi to Market Afrezza the Inhaled Insulin Medication

Sanofi, a pharmaceutical company in France, has agreed to purchase the right to market Afrezza for $925 million. The drug was recently approved as an inhaled insulin treatment for diabetics that was developed by California based MannKind Corporation. Sanofi, which is Paris-based, said it was paying MannKind $150 million upfront. Alfred Mann is the entrepreneur physicist who owns MannKind. Following the first upfront payment, MannKind will receive up to $775 million more if certain regulatory and sales milestones are met. Sanofi plans to start sales... 
 

Roche to Acquire Seragon in U.S. for $1.7 Billion

Roche Holding AG announced that it would spend as much as $1.725 billion to purchase Seragon Pharmaceuticals, a U.S. biotech privately held company that researches treatments for breast cancer. Roche for very a long period of time has dominated the breast cancer field with drugs like Herceptim and just recently was given approval for Perjeta and Kadcyla, two other treatments for patients that have cancer cells that contain higher amounts of HER2 protein. Seragon, based in San Diego, was spun off last year from Aragon Pharmaceuticals when it was... 
 

AbbVie Bid for Shire Rejected as Low

Shire Plc has rejected a takeover bid of 27.3 million pounds or $46.5 million from AbbVie Inc as too low. This is the most recent attempt by a healthcare company from the U.S. to lower its corporate taxes by relocating to the United Kingdom. The offer, which was approximately 46.10 pounds per share, undervalues the company said Shire in an official statement. Shire shares surged up over 16% in trading, but the board at the drug maker unanimously rejected AbbVie’s bid. At this time, there are no ongoing talks and there is no certainty any further... 
 

Ex-Glaxo Chief in China Caught Up in Bribery Allegations

On Wednesday, China accused the former chief to GlaxoSmithKline in China of ordering his staff to commit bribery that resulted in revenue in the billions of yuan. Officials from the Ministry of Public Security in China at a briefing with the press alleged that Mark Reilly a UK national and former executive ordered his team of salespeople as well as other staff members to bribe organizations in healthcare, doctors and other parties to increase the sale of drugs for the company in China. An official with the ministry, Gao Feng, headed the government’s... 
 

Bayer AG Acquiring Consumer Business from Merck

Bayer AG, based in Germany, is acquiring the consumer business of Merck for an estimated $14.2 billion. Bayer will now be the owners of brands that are well known including Afrin, Coppertone and Claritin. The deal means the German based pharmaceutical giants will have a list of U.S. brands selling at pharmacies with the idea of expanding their sales over a broader global market. While the brands are already in markets around the world, the majority of their sales currently are based in the United States. Bayer, which is best known for aspirin, summed... 
 

Pfizer Reports Weaker Profits

Pfizer Inc the United States based pharmaceutical giant said its profit in the first quarter shrank by 15% due to weaker revenue in both of its largest businesses. The U.S. drug maker did not comment when it released its earnings about its attempt to acquire AstraZeneca, except to mention because of UK Takeover Code rules the company is not allowed currently to update or confirm its bottom line earnings guidance per share for 2014. Pfizer did confirm adjusted earnings and adjusted revenue guidance of 2014 that had been previously reported. Pfizer... 
 

AstraZeneca Offered $100 Billion by Pfizer

AstraZenca, the Anglo-Swedish pharmaceutical company saw it shares spike by 15% Monday after Pfizer the U.S. pharmaceutical giant said it had offered the company close to $100 billion to buy it. Pfizer, which is the maker of the famous blue pill Viagra, said its initial approach was rejected by AstraZeneca in January. The shares and cash deal would represent a premium of 30% on the closing stock price of AstraZeneca on January 3 of 35.26 pounds. AstraZeneca said the proposal had substantially undervalued the company and its future prospects. On... 
 

CVS Caremark Profit Increase by 12% in Fourth Quarter

Shares at CVS Caremark outpaced Tuesday’s broader market after the pharmacy chain increased its forecast for earnings for the beginning of 2014 and reassured its investors that its business could absorb the hit financially that was coming from its decision to stop the sales of tobacco in all of its stores. The company, based in Woonsocket, Rhode Island also reported earnings for the fourth quarter had climbed by over 12% and passed the expectations of Wall Street. CVS Caremark gained attention across the nation last week when it promised to phase... 
 

GlaxoSmithKline Stops Paying Doctors for Promotion of Drugs

GlaxoSmithKline the British pharmaceutical giant announced on Tuesday that it was stopping its payments to doctors who speak on behalf of the company. GSK also announced that pay for sales representatives would not be tied to how many doctor’s prescriptions were written. The move by the British drug maker ends two industry practices that had been heavily criticized. GSK announced it would no longer pay doctors to make speeches about its drugs or what types of diseases the drugs treated. Influencing prescriptions has been a long time practice in... 
 

Shire to Acquire ViroPharma for $4.2 Billion

Shire, based in Dublin announced on Monday that it had agreed to acquire ViroPharma for $4.2 billion to expand its rare disease treatments portfolio. The company said it agreed to pay $50 a share for the Pennsylvania based ViroPharma, which is 27% higher than the Friday price at closing and a premium of 64% over its September 12 close, when speculation first surfaced that the company had been reconsidering its future. While a number of companies in the pharmaceutical industry are opening their wallets to bring aboard innovative treatments aimed... 
 

Johnson & Johnson to Pay Penalty of $2.2 Billion

Johnson & Johnson agreed it would pay over $2.2 billion in order to settle civil and criminal claims that it had marketed Risperdal, its antipsychotic drug as well as other medications for uses off-label and paid large kickbacks to a pharmacy, announced the Department of Justice on Monday. This agreement, which is one of the largest fraud settlements in the health care industry, largely was centered on the antipsychotic medication Risperdal that J&J marketed for the treatment of dementia in elderly patients and in children that suffered... 
 

Pfizer Beats Wall Street Estimates

Pfizer, Inc., the biggest drug maker in the world reported profits for the third quarter that passed the estimates of analysts as the drug maker lowered its costs, while its sales of its top painkiller and vaccine increased. Earnings with the exception of one-time items ended the quarter at 58 cents per share, which was 2 cents per share higher than analysts’ estimates. Sales dropped by 2% to end the quarter at $12.6 billion, from last year’s $13 billion. Pfizer is expanding its sales of Prevenar, its pneumococcal vaccine, which is the company’s... 
 

Profit Falls at Merck on Lower Sales

Merck and Co’s earnings for the third quarter dropped by 35% as it lost the exclusivity for Singulair the allergy and asthma drug that contributed to the pharmaceutical giant’s weaker sales. Merck said expenses related to the restructuring of the research and development sector of the company also contributed to the performance by the company. The company also narrowed its earnings estimate per share from 2013 from $3.45 to $3.55 to $3.48 to $3.52 and affirmed its outlook on revenue. Recently Merck unveiled a plan for global reorganization to... 
 

Actelion Reaches High of Six Years

Actelion the Swiss biotech company saw its shares climb over 5% to their highest since 2007 on Monday. Its stock prices increased on optimism that it had a viable product to gain sales and earn profit after an approval in the U.S. for its new lung and heart drug. The U.S. Food and Drug Administration gave its approval to the Swiss biotech  company’s new pulmonary arterial hypertension drug known as Opsumit late Friday. It did not put a black box warning that requires ongoing mandatory testing on the liver. This will give the new medication an... 
 

Executives of British Drug Maker Investigated for Bribes

The police in China announced on Monday that British pharmaceutical giant GlaxoSmithKline had channeled millions of dollars worth of bribes through travel agents in China to doctors and government officials. The bribes helped GSK to increase its prices and sales of their medications in China, said authorities. Law enforcement authorities detained four top executives at GSK. All four executives are from China. An economic crimes unit chief said that the government of China discovered that since 2008 the British drug maker had funneled over $489 million... 
 

Hospital Chain Tenet Acquires Vanguard Health

Tenet Healthcare, a US hospital operator, announced that it will acquire its rival Vanguard Health Systems for $1.73 billion. It would give it a better position to benefit from President Barack Obama’s healthcare reform. Investors expect revenue from hospitals to grow from treating more Americans insured under Obama’s healthcare reform law. There are speculations that major hospital chains’ acquisitions would improve the value of their stocks. Providers not only prepare for the healthcare overhaul, they are also coping with the slowdown in... 
 

Tenet Acquiring Vanguard Health in Deal for $1.8 Billion

Vanguard Health Systems, a hospital operator, will be acquired by Tenet Healthcare Corp, for an estimated $1.8 billion so Tenet can expand into more hospitals in Texas. The deal will have Tenet paying $21 per share, said the companies in a joint statement. The $21 price is 70% above the closing price as of June 21 of $12.37 on NYSE for Vanguard, based in Nashville, Tennessee. Tenet will also assume debt for Vanguard of over $2.5 billion. The acquisition by Tenet, based in Dallas, Texas, will give it 28 hospitals in different regions of the country... 
 

Actavis to acquire Warner Chilcott

Actavis, the generic drug maker, has been talked about over speculation of being taken over, is planning to buy Ireland’s Warner Chilcott the specialty pharmaceutical firm for a price of $5 billion. Both companies announced the deal would be all in stock and has a value including all debt of more than $8.5 billion. This move comes at a time when Actavis spurned the approaches of Valeant Pharmaceutical International a pharmaceutical company based in Canada, as well as from Mylan, Inc. Pharmaceutical analysts said if the acquisition by Actavis of... 
 

Healthcare Sector Leads Wall Street Increase

Stocks increased Tuesday, which was headed by the healthcare sector. The rally came after the government announced its decision on payment rates. Investors also felt optimistic after the release of the report on factory orders that confirmed the economy is improving at a steady rate. The Standard & Poor’s 500 Index closed at another record high but it fell short of reaching its all-time intraday high of 1,576.09. The Dow also reached another record high. The US government announced it would drop the plans to slash payments for private Medicare... 
 

Justice Department Settles Online Pharmacy Probe with UPS

The U.S. Justice Department announced it had reached an agreement for $40 million Friday to settle charges against UPS that the giant shipping company had done business with Internet pharmacies that were illegal. U.S. officials agreed as part of the settlement not to file prosecution charges against UPS in exchange for UPS handing over the $40 million the company received from its business dealings with the illicit pharmacies operating online. Another requisite of the deal is that UPS implement a strict compliance program. The Justice Department... 
 

Pharmaceuticals Give Large Sums of Money to Physicians

Most patients are unaware that different pharmaceutical companies give doctors thousands of dollars for each patient that they enrol in experimental drug trials. Even though the motive’s of the doctor’s may be pure and the medications are what is best for the patient’s sickness, patients need to be know about such payments to discuss them with the doctor and then decided for themselves if the participation by the doctor in the trial might cause his medical advice to be compromised. The healthcare reform legislation has a provision that should... 
 

Profit at Merck Falls in Fourth Quarter

Merck, the pharmaceutical giant based in Whitehouse Station, New Jersey, announced that profits fell in the fourth quarter of 2012 by 7%. Company officials said that was due in part to sales of Singulair, its best selling asthma medication, dropping because of competition from generic medications. The company also announced that it was postponing an attempt to have its osteoporosis medication approved by the U.S. Food and Drug Administration. The new drug had been highly anticipated. Merck officials release the fourth quarter as well as full year... 
 

FDA Approves New Use for Pfizer Vaccine

Pfizer received approval from the U.S. Food and Drug Administration on Friday to use Prevnar 13 in children and adolescents between the age of 6 and 17 to prevent Invasive Pneumococcal Disease. Prevnar 13 becomes the first and just the only Pneumococcal Conjugate Vaccine that has been approved for this particular age group. Pfizer announced the FDA’s approval for expanded use of the vaccine in a Friday press release. In this age group, the vaccine will be administered via a one-time only dose to those who have not received Prevnar 13 previously. Pfizer... 
 

Johnson & Johnson Diabetes Drug Gets Advisory Board Approval

On Thursday, a new drug being developed by Johnson & Johnson was given backing by an advisory panel that voted 10 to 5 in favor of recommending the drug to the U.S. Food and Drug Administration. If approved, the drug would be the first of a new type of medication in the United States that treats diabetes. Nevertheless, a number of the panel members raised concerns over the drug’s potential risks when used in patients suffering from impaired kidneys. They also were concerned with the cardiovascular risks the medication might have. The drug... 
 

Anti-Clotting Drug Approved by FDA

Eliquis, the anti-clotting drug by Bristol-Myers Squibb and Pfizer was approved on Friday by the U.S. Food and Drug Administration. The FDA approval had been long anticipated by many cardiologists and is considered the next blockbuster for Bristol-Myers, which will be in charge of manufacturing the new drug, while Pfizer will market the new drug. The drug was approved by the U.S. regulatory agency for use in lowering the risk of stroke and blood clots in those who have arterial fibrillation, an arrhythmia in the heart that afflicts millions throughout... 
 

Draftfcb Healthcare Acquires Hudson Global, Retains Management Team

Interpublic Group (NYSE:IPG) subsidiary Draftfcb Healthcare announced today that they are acquiring N.Y.-based pharmaceutical marketing company Hudson Global which offers integrated marketing solutions aimed at the pharmaceutical industry. Hudson Global will be situated under Draftfcb and the company said that the acquisition will “create a top 5 healthcare offering in the United States.” “Our acquisition of Hudson is part of a long-term plan to make strategic acquisitions that will bolster our clients’ businesses and strengthen... 
 

Jazz Pharma (JAZZ) Wraps Up EUSA Pharma Acquisition

Jazz Pharmaceuticals (NASDAQ:JAZZ) has announced that they have wrapped up their acquisition of privately-held EUSA Pharma for $680 million in cash and notes it is accretive to their earnings and expect incremental modified EPS of $0.25 to $0.30 in 2012.  Jazz Pharma will retain the EUSA name in international business. “This transaction furthers our mission to improve patients’ lives by growing our portfolio of specialty therapies that address significant medical needs,” said Bruce Cozadd, chairman and chief executive officer... 
 

Omnicell (OMCL) Completes MTS Medication Tech Bid

Omnicell, Inc., (NASDAQ:OMCL) announced today it has completed its acquisition of MTS Medication Technologies, Inc., which the company had previously stated on May 2nd, 2012 that it intended to do. Randall Lipps, chairman, president and CEO of Omnicell had the following to say, “Providing medication management solutions across the entire spectrum of health care is aligned with the needs of our customers to increase efficiency by reducing recurrences of patient treatment needs.  We believe that the addition of MTS to the existing Omnicell... 
 

OriGene Technologies Acquires Beijing Zhongshan Golden Bridge Biotechnology

OriGene Technologies, Inc. announced today the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). Founded in the year 1993, ZsBio provides testing products (pathology) within their domestic Chinese market, such as oncology diagnostics. OriGene had the following to say regarding today’s acquisition, “With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene,” said Wei-Wu He, CEO of OriGene.  “ZsBio is already a leader in pathology products for... 
 

Abbott Laboratories (ABT) Announces Initiation of ESPRIT I

Abbott Laboratories (NYSE:ABT) announced today that they are initiating ESPRIT I which the company says is a first-of-its-kind clinical trial in Europe. The trial is for performance evaluation of Esprit.  The drug itself is a bioresorbable vascular scaffold (BVS) and is for “treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudicatio,” according to Abbot, which also states that claudication is a common symptom in patients with peripheral artery disease (PAD) and “associated... 
 
© 2006-2019 Ticker Report